Hematopoietic Cell Transplantation for Ovarian Cancer

Autologous hematopoietic cell transplantation (including tandem autologous transplants) is covered for ovarian germ cell tumors as salvage therapy for relapsed disease responsive to standard chemotherapy and as consolidation for complete remission (CPT 38232/38241 and HCPCS S2150 when selection criteria are met). Hematopoietic cell transplantation is considered experimental/investigational and not covered as initial frontline therapy in place of standard FDA‑approved chemotherapy, for allogeneic transplants for germ cell tumors, or for any autologous/allogeneic transplant to treat epithelial ovarian cancer (high‑dose chemo with autologous SCT should be restricted to clinical trials).

"Hematopoietic cell transplantation for ovarian cancer is considered experimental and investigational in any of the following scenarios (not an all-inclusive list) because the effectiveness has not ..."